Nexien BioPharma Files 10-Q for Q3 2025
| Field | Detail |
|---|---|
| Company | Nexien Biopharma, Inc. |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biopharma, financials
Related Tickers: NXEN
TL;DR
Nexien BioPharma (NXEN) filed its Q3 2025 10-Q. Check financials.
AI Summary
Nexien BioPharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Intiva BioPharma Inc. and Kinder Holding Corp., is in the pharmaceutical preparations industry. Their business address is in Glendale, Colorado.
Why It Matters
This filing provides investors with an update on Nexien BioPharma's financial performance and operational status for the third quarter of fiscal year 2025.
Risk Assessment
Risk Level: medium — As a biopharma company, Nexien BioPharma is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- NEXIEN BIOPHARMA, INC. (company) — Filer
- Intiva BioPharma Inc. (company) — Former Company Name
- Kinder Holding Corp. (company) — Former Company Name
- 20250331 (date) — Period of Report
- 20250514 (date) — Filed as of Date
FAQ
What is the reporting period for this 10-Q filing?
The conforming period of report is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed as of May 14, 2025.
What were Nexien BioPharma's former company names?
Nexien BioPharma was formerly known as Intiva BioPharma Inc. and Kinder Holding Corp.
What is Nexien BioPharma's Standard Industrial Classification code?
The SIC code for Nexien BioPharma is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's business address?
The business address is 4340 E Kentucky Ave, Suite 206, Glendale, CO 80246.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding NEXIEN BIOPHARMA, INC..